Aclaris Therapeutics, Inc.
ACRSNASDAQHealthcareBiotechnology
As of Oct 15, 2026 close
- Market cap
- $498.15M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $1.83$6.60
- Volume (live)
- -
- Avg. volume (3M)
- 3.67M
Aclaris Therapeutics (ACRS) Stock Price & Financial Analysis
Aclaris Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $3.34 - $3.51 |
|---|---|
| 52-Week High | $6.60 |
| 52-Week Low | $1.83 |
| Open | $3.42 |
| Volume (last close) | 2.59M |
| Average Volume (3M) | 3.67M |
| Revenue (TTM) | 8.22M |
|---|---|
| Net Income (TTM) | -75.74M |
| Free Cash Flow (TTM) | -62.18M |
| EPS (TTM) | −$0.59 |
| Profit Margin | -921.50% |
| Operating Margin | -1046.51% |
| Return on Equity (ROE) | -60.79% |
| Debt to Equity | 0.00 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 498.15M |
|---|---|
| Shares Outstanding | 142.74M |
| Price to Sales (P/S) | 60.61 |
| Price to Book (P/B) | 4.00 |
| EV/EBITDA | -6.17 |
| 50-Day MA | $5.44 |
|---|---|
| 200-Day MA | $4.47 |
| 1-Year Change | +70.24% |
Source: Market prices and company fundamentals. Data as of Oct 15, 2026. Data sources and methodology
Aclaris Therapeutics at a Glance
As of the Oct 15, 2026 close, Aclaris Therapeutics (ACRS) has a market capitalization of $498.15M. The stock trades at 60.6× sales. Over the trailing twelve months it lost $75.74M on revenue of $8.22M and burned $62.18M of free cash flow. Revenue fell 51.0% year over year.
As of its latest reported balance sheet, it holds $19.17M in cash and securities against $0.00 of debt, a net cash position of $19.17M.
Aclaris Therapeutics does not currently pay a dividend.
The share price is up 70.2% over the past year. At $3.49 (the Oct 15, 2026 close) it sits within its 52-week range of $1.83 to $6.60, below its 200-day moving average of $4.47.
Based on 6 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $12.00, 243.8% above the Oct 15, 2026 close.
Frequently Asked Questions About Aclaris Therapeutics
What is the current stock price for ACRS?
As of the Oct 15, 2026 close, ACRS stock trades at $3.49. The 52-week range is $1.83–$6.60, with a day range of $3.34–$3.50.
What is the P/E ratio for ACRS?
The P/E ratio (Price-to-Earnings) for ACRS is shown in the Key Statistics section. This valuation metric helps compare Aclaris Therapeutics, Inc. to industry peers.
Does ACRS pay dividends?
Aclaris Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for ACRS?
Based on ratings from 6 professional analysts over the last 90 days, the consensus for ACRS is Buy. The average 12-month price target is $12.00, a 243.8% upside from the Oct 15, 2026 close of $3.49.
What is the market cap of ACRS?
As of the Oct 15, 2026 close, Aclaris Therapeutics's market capitalization is $498.2M, classifying it as a small-cap company. Aclaris Therapeutics operates in the Healthcare sector within the Biotechnology industry.